JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anne Samuel maintains an Overweight rating on Evolent Health (EVH) but lowers the price target from $53 to $52.

March 15, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Evolent Health but lowers the price target from $53 to $52.
The adjustment in price target by JP Morgan, while maintaining an Overweight rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. This could lead to a neutral short-term impact on EVH's stock price as the market digests the minor adjustment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100